Primary structures of PYY, [Pro34]PYY, and PYY-(3-36) confer different conformations and receptor selectivity

被引:99
作者
Keire, DA
Mannon, P
Kobayashi, M
Walsh, JH
Solomon, TE
Reeve, JR
机构
[1] Greater Los Angeles Vet Affairs Healthcare Syst, CURE Digest Dis Res Ctr, Los Angeles, CA 90073 USA
[2] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA
[3] Vet Affairs Med Ctr, Durham, NC 27705 USA
[4] Duke Univ, Med Ctr, Durham, NC 27705 USA
[5] Univ Calif Los Angeles, Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2000年 / 279卷 / 01期
关键词
peptide YY; Y-1; receptor; Y-2; circular dichroism; nuclear magnetic resonance; three-dimensional structure;
D O I
10.1152/ajpgi.2000.279.1.G126
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We synthesized PYY-(1-36) (nonselective between Y-1 and Y-2 receptor subtype agonists), [Pro(34)]-PYY (selective for Y-1), and PYY-(3-36) (selective for Y-2) to determine whether solution conformation plays a role in receptor subtype selectivity. The three peptides exhibited the expected specificities in displacing labeled PYY-(1-36) from cells transfected with Y-1 receptors (dissociation constants = 0.42, 0.21, and 1,050 nM, respectively) and from cells transfected with Y2 receptors (dissociation constants = 0.03, 710, and 0.11 nM, respectively) for PYY-(1-36), [Pro(34)]PYY, and PYY-(3-36). Sedimentation equilibrium analyses revealed that the three PYY analogs were 80-90% monomer at the concentrations used for the subsequent circular dichroism (CD) and H-1-nuclear magnetic resonance (NMR) studies. CD analysis measured helicities for PYY-(1-36), [Pro(34)]PYY, and PYY-(3-36) of 42%, 31%, and 24%, suggesting distinct differences in secondary structure. The backbone H-1-NMR resonances of the three peptides further substantiated marked conformational differences. These patterns support the hypothesis that Y-1 and Y-2 receptor subtype binding affinities depend on the secondary and tertiary solution state structures of PYY and its analogs.
引用
收藏
页码:G126 / G131
页数:6
相关论文
共 30 条
[1]   EFFECT OF PEPTIDE-YY ON GASTRIC, PANCREATIC, AND BILIARY FUNCTION IN HUMANS [J].
ADRIAN, TE ;
SAVAGE, AP ;
SAGOR, GR ;
ALLEN, JM ;
BACARESEHAMILTON, AJ ;
TATEMOTO, K ;
POLAK, JM ;
BLOOM, SR .
GASTROENTEROLOGY, 1985, 89 (03) :494-499
[2]   COMPLETE L-ALANINE SCAN OF NEUROPEPTIDE-Y REVEALS LIGANDS BINDING TO Y-1 AND Y-2 RECEPTORS WITH DISTINGUISHED CONFORMATIONS [J].
BECKSICKINGER, AG ;
WIELAND, HA ;
WITTNEBEN, H ;
WILLIM, KD ;
RUDOLF, K ;
JUNG, G .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 225 (03) :947-958
[3]   STRUCTURE-ACTIVITY-RELATIONSHIPS OF NEUROPEPTIDE-Y ANALOGS WITH RESPECT TO Y-1 AND Y-2 RECEPTORS [J].
BECKSICKINGER, AG ;
JUNG, G .
BIOPOLYMERS, 1995, 37 (02) :123-142
[4]   PEPTIDE YY IS A PHYSIOLOGICAL REGULATOR OF WATER AND ELECTROLYTE ABSORPTION IN THE CANINE SMALL-BOWEL IN-VIVO [J].
BILCHIK, AJ ;
HINES, OJ ;
ADRIAN, TE ;
MCFADDEN, DW ;
BERGER, JJ ;
ZINNER, MJ ;
ASHLEY, SW .
GASTROENTEROLOGY, 1993, 105 (05) :1441-1448
[5]   Y-receptor subtypes - How many more? [J].
Blomqvist, AG ;
Herzog, H .
TRENDS IN NEUROSCIENCES, 1997, 20 (07) :294-298
[6]   X-RAY-ANALYSIS (1.4-A RESOLUTION) OF AVIAN PANCREATIC-POLYPEPTIDE - SMALL GLOBULAR PROTEIN HORMONE [J].
BLUNDELL, TL ;
PITTS, JE ;
TICKLE, IJ ;
WOOD, SP ;
WU, CW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (07) :4175-4179
[7]   COEXISTENCE OF GLICENTIN AND PEPTIDE-YY IN COLORECTAL L-CELLS IN CAT AND MAN - AN ELECTRON-MICROSCOPIC STUDY [J].
BOTTCHER, G ;
ALUMETS, J ;
HAKANSON, R ;
SUNDLER, F .
REGULATORY PEPTIDES, 1986, 13 (3-4) :283-291
[8]   CENTRAL INHIBITORY-ACTION OF PEPTIDE YY ON GASTRIC-MOTILITY IN RATS [J].
CHEN, CH ;
ROGERS, RC .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1995, 269 (04) :R787-R792
[9]   DETERMINATION OF HELIX AND BETA-FORM OF PROTEINS IN AQUEOUS-SOLUTION BY CIRCULAR-DICHROISM [J].
CHEN, YH ;
YANG, JT ;
CHAU, KH .
BIOCHEMISTRY, 1974, 13 (16) :3350-3359
[10]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099